Thalidomide in COVID19
Phase 3
Recruiting
- Conditions
- COVID19.disease diagnosis of COVID-19 confirmed by laboratory testing.U07.1
- Registration Number
- IRCT20170207032444N3
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
18-75 year old men and 50-75 year old women admitted in hospital
Spo2 less than 85% in admission
Clinical symptoms and signs compatible with COVID19 infection and positive PCR test or lung HRCT abnormalities compatible with COVID19 pneumonia
No need to intubation in first 24 hour of admission
No multiorgan failure at presentation
No shock state at presentation
Obtained informed consent
Exclusion Criteria
Hepatic failure (Child Pugh score = C, AST> 5 times of the upper limit normal)
Severe renal dysfunction (GFR less than 30cc per min)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of Thalidomide in severe Covid19 pneumonia. Timepoint: Daily until discharge and then weekly until 28 days. Method of measurement: history, pulse oximetry, sphygmomanometer.
- Secondary Outcome Measures
Name Time Method 28 days survival rate. Timepoint: daily until discharge and then weekly until 28 days. Method of measurement: history.